SG Americas Securities LLC raised its position in Nektar Therapeutics (NASDAQ:NKTR) by 86.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,584 shares of the biopharmaceutical company’s stock after buying an additional 20,209 shares during the period. SG Americas Securities LLC’s holdings in Nektar Therapeutics were worth $2,128,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Asset Management One Co. Ltd. acquired a new position in shares of Nektar Therapeutics during the first quarter worth approximately $110,000. Daiwa Securities Group Inc. acquired a new position in shares of Nektar Therapeutics during the first quarter worth approximately $111,000. We Are One Seven LLC acquired a new position in shares of Nektar Therapeutics during the first quarter worth approximately $118,000. Harbor Advisors LLC acquired a new position in shares of Nektar Therapeutics during the first quarter worth approximately $213,000. Finally, Canandaigua National Bank & Trust Co. acquired a new position in shares of Nektar Therapeutics during the first quarter worth approximately $219,000. Hedge funds and other institutional investors own 92.56% of the company’s stock.

In other Nektar Therapeutics news, Director R Scott Greer sold 1,400 shares of the company’s stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $61.99, for a total value of $86,786.00. Following the completion of the sale, the director now owns 131,733 shares of the company’s stock, valued at $8,166,128.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Howard W. Robin sold 130,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 27th. The shares were sold at an average price of $49.52, for a total transaction of $6,437,600.00. Following the completion of the sale, the chief executive officer now directly owns 267,690 shares of the company’s stock, valued at approximately $13,256,008.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 263,984 shares of company stock valued at $14,141,404. 4.31% of the stock is currently owned by insiders.

NKTR opened at $66.11 on Wednesday. The company has a quick ratio of 19.55, a current ratio of 19.67 and a debt-to-equity ratio of 0.13. The company has a market cap of $11.02 billion, a P/E ratio of -120.20 and a beta of 2.08. Nektar Therapeutics has a fifty-two week low of $18.90 and a fifty-two week high of $111.36.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $5.22 by $0.11. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.03 billion. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. Nektar Therapeutics’s revenue for the quarter was up 3043.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.39) earnings per share. equities research analysts anticipate that Nektar Therapeutics will post 3.66 earnings per share for the current fiscal year.

A number of equities analysts have recently issued reports on NKTR shares. HC Wainwright lowered shares of Nektar Therapeutics from a “buy” rating to a “neutral” rating and set a $54.00 target price on the stock. in a research report on Monday, June 11th. Cowen reiterated a “buy” rating and set a $86.00 target price on shares of Nektar Therapeutics in a research report on Thursday, August 9th. ValuEngine upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. William Blair reiterated a “buy” rating on shares of Nektar Therapeutics in a research report on Monday, June 4th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Nektar Therapeutics from $90.00 to $78.00 and set an “overweight” rating on the stock in a research report on Monday, June 4th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Nektar Therapeutics has an average rating of “Buy” and an average target price of $82.91.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

See Also: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.